Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04945018
PHASE1/PHASE2

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)

Sponsor: Heartseed Inc.

View on ClinicalTrials.gov

Summary

The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.

Official title: A Phase I/II Study of Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Severe Heart Failure, Secondary to Ischemic Heart Disease

Key Details

Gender

All

Age Range

20 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2022-04-19

Completion Date

2026-01-31

Last Updated

2025-09-22

Healthy Volunteers

No

Interventions

BIOLOGICAL

HS-001 CS

Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension

DEVICE

HS-001-D needle, HS-001-D Adaptor

Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors

Locations (8)

St. Marianna University Hospital

Kawasaki, Japan

Saitama Medical University International Medical Center

Saitama, Japan

Juntendo University Hospital

Tokyo, Japan

Nihon University Itabashi Hospital

Tokyo, Japan

The University of Tokyo Hospital

Tokyo, Japan

Tokyo Medical and Dental University Medical Hospital

Tokyo, Japan

Tokyo Metropolitan Geriatric Medical Center

Tokyo, Japan

Tokyo Women's Medical University

Tokyo, Japan